Stock AnalizVerastem, Inc. VSTM
Biotechnology: Pharmaceutical Preparations · IPO 2012 · data as of November 13, 2026
Verastem, Inc. (VSTM) is a healthcare company listed in the US with a market value of about $1.0B. In the twelve months to September 30, 2026 it had revenue of $100M and net income of -$179M, a net margin of -178.4%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -19% a year, a 5-year average ROIC of -204%.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100M | $31M | $10M | — | $3M | $2M | $89M | $17M | $27M | — | — |
| Net income | -$179M | -$209M | -$131M | -$87M | -$74M | -$71M | -$68M | -$149M | -$72M | -$68M | -$36M |
| Free cash flow | -$168M | — | -$105M | — | — | -$54M | -$34M | -$139M | -$76M | — | -$30M |
| EPS (diluted) | $-1.84 | $-3.02 | $-3.66 | $-3.96 | $-4.57 | $-4.90 | $-0.01 | $-24.00 | $-16.44 | $-21.12 | $-11.88 |
| Net margin | -178.4% | -677.6% | -1306.4% | — | -2843.3% | -3468.1% | -76.5% | -854.8% | -271.1% | — | — |
| ROIC | — | -100.2% | -679.7% | -73.5% | -99.0% | -67.9% | -32.8% | -286.6% | -65.9% | -0.4% | -40.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $17.22, 111% above the current price; targets range from $12.00 to $24.00; the consensus rating is “Strong buy”; expected EPS is $-1.90 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Verastem pay a dividend?
Not currently.
Is Verastem a good stock to buy?
We do not give buy or sell advice. Verastem scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.